# Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

> **NCT00519896** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 35 (actual)

## Conditions studied

- Recurrent Thyroid Cancer
- Stage IVA Follicular Thyroid Cancer
- Stage IVA Papillary Thyroid Cancer
- Stage IVB Follicular Thyroid Cancer
- Stage IVB Papillary Thyroid Cancer
- Stage IVC Follicular Thyroid Cancer
- Stage IVC Papillary Thyroid Cancer
- Thyroid Gland Medullary Carcinoma

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00519896
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519896, "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00519896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*